Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>On August 14, 2024, Cocrystal Pharma, Inc. (COCP) announced financial results for the second quarter of 2024 and provided a business update.</li><li>In the second half of 2024, we anticipate topline results from the Phase 2a trial of CC-42344, which is a live virus challenge study.</li><li>The company plans to file an Investigational New Drug (IND) application in 2025 to conduct the next study of CC-42344 in the U.S. In addition, planning is underway for a Phase 1 study in healthy volunteers to evaluate inhaled CC-42344 as a potential prophylactic and therapeutic for influenza A.</li></ul>

On August 14, 2024, Cocrystal Pharma, Inc. (COCP) announced financial results for the second quarter of 2024 and provided a business update.In the second half of 2024, we anticipate topline results from the Phase 2a trial of CC-42344, which is a live virus challenge study.The company plans to file an Investigational New Drug (IND) application in 2025 to conduct the next study of CC-42344 in the U.S. In addition, planning is underway for a Phase 1 study in healthy volunteers to evaluate inhaled CC-42344 as a potential prophylactic and therapeutic for influenza A.

COCP: Topline Results from Phase 2a Study of CC-42344 in 2H24 